H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) yesterday and set a price target ...

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...

H.C. Wainwright reaffirmed their positive stance on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and a price target of $18.00, representing significant upside potential from the current price ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...

Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In September, the FDA issued a Complete Response Letter to the company.

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ ...